Nurix Historical Financial Ratios
NRIX Stock | USD 16.86 0.91 5.71% |
Nurix Therapeutics is lately reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 4.14 will help investors to properly organize and evaluate Nurix Therapeutics financial condition quickly.
Nurix |
About Nurix Financial Ratios Analysis
Nurix TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Nurix Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Nurix financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Nurix Therapeutics history.
Nurix Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Nurix Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Nurix Therapeutics sales, a figure that is much harder to manipulate than other Nurix Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Nurix Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Nurix Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nurix Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Nurix Stock please use our How to Invest in Nurix Therapeutics guide.At this time, Nurix Therapeutics' Shareholders Equity Per Share is fairly stable compared to the past year. Graham Net Net is likely to rise to 2.34 in 2024, whereas Price To Sales Ratio is likely to drop 4.80 in 2024.
2021 | 2022 | 2023 (projected) | Current Ratio | 4.51 | 3.4 | 3.06 | Net Debt To EBITDA | 0.29 | 0.17 | 0.2 |
Nurix Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Nurix Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Nurix Therapeutics fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 37.49 | 41.55 | 15.59 | 4.39 | 5.05 | 4.8 | |
Ptb Ratio | 2.3 | 3.61 | 1.98 | 1.69 | 1.52 | 1.59 | |
Book Value Per Share | 18.52 | 7.98 | 6.25 | 3.69 | 3.32 | 4.35 | |
Free Cash Flow Yield | (0.001422) | (0.006936) | (0.0728) | (0.29) | (0.27) | (0.31) | |
Invested Capital | (0.08) | 0.0263 | 0.0381 | 0.0394 | 0.15 | 0.14 | |
Stock Based Compensation To Revenue | 0.24 | 0.53 | 0.73 | 0.44 | 0.39 | 0.31 | |
Capex To Depreciation | (2.09) | (0.93) | (1.13) | (0.62) | (0.71) | (0.74) | |
Pb Ratio | 2.3 | 3.61 | 1.98 | 1.69 | 1.52 | 1.59 | |
Ev To Sales | 30.79 | 39.29 | 14.23 | 4.08 | 4.69 | 4.46 | |
Free Cash Flow Per Share | (0.3) | (2.1) | (3.54) | (1.65) | (1.9) | (1.99) | |
Roic | (0.15) | (0.33) | (0.54) | (0.67) | (0.77) | (0.73) | |
Net Income Per Share | (2.76) | (2.73) | (3.42) | (2.65) | (3.05) | (3.2) | |
Sales General And Administrative To Revenue | 0.92 | 1.05 | 0.98 | 0.56 | 0.5 | 0.53 | |
Research And Ddevelopement To Revenue | 3.73 | 3.91 | 4.78 | 2.36 | 2.12 | 2.3 | |
Capex To Revenue | (0.0531) | (0.26) | (0.19) | (0.32) | (0.11) | (0.13) | |
Cash Per Share | 17.94 | 6.89 | 6.36 | 5.3 | 4.77 | 5.32 | |
Pocfratio | (8.4K) | (14.65) | (3.77) | (4.15) | (3.74) | (3.93) | |
Capex To Operating Cash Flow | 56.91 | 0.0671 | 0.0766 | 0.1 | 0.12 | 0.11 | |
Pfcf Ratio | (144.18) | (13.73) | (3.5) | (3.77) | (3.39) | (3.56) | |
Days Payables Outstanding | 18.73 | 399.09 | 171.02 | 171.11 | 154.0 | 123.66 | |
Income Quality | 0.00185 | 0.72 | 0.89 | 0.57 | 0.65 | 1.01 | |
Roe | (0.15) | (0.34) | (0.55) | (0.72) | (0.83) | (0.78) | |
Ev To Operating Cash Flow | (6.9K) | (13.85) | (3.44) | (3.86) | (3.47) | (3.65) | |
Pe Ratio | (15.45) | (10.55) | (3.63) | (2.35) | (2.11) | (2.22) | |
Return On Tangible Assets | (0.11) | (0.24) | (0.4) | (0.39) | (0.45) | (0.48) | |
Ev To Free Cash Flow | (118.42) | (12.98) | (3.2) | (3.5) | (3.15) | (3.31) | |
Earnings Yield | (0.0647) | (0.0948) | (0.28) | (0.43) | (0.49) | (0.47) | |
Net Debt To E B I T D A | 1.84 | 0.57 | 0.29 | 0.17 | 0.2 | 0.19 | |
Current Ratio | 2.44 | 6.7 | 4.7 | 4.51 | 3.4 | 3.06 | |
Tangible Book Value Per Share | 18.52 | 7.98 | 6.25 | 3.69 | 3.32 | 4.35 | |
Graham Number | 33.91 | 22.15 | 21.91 | 14.83 | 13.35 | 13.68 | |
Shareholders Equity Per Share | 18.52 | 7.98 | 6.25 | 3.69 | 3.32 | 4.35 | |
Debt To Equity | (0.08) | 0.0263 | 0.0381 | 0.0394 | 0.15 | 0.14 | |
Capex Per Share | (0.29) | (0.13) | (0.25) | (0.15) | (0.18) | (0.19) | |
Graham Net Net | 11.71 | 3.87 | 4.04 | 2.29 | 2.06 | 2.34 | |
Revenue Per Share | 1.14 | 0.69 | 0.79 | 1.42 | 1.63 | 1.31 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.COST | Costco Wholesale Corp | |
AMZN | Amazon Inc | |
AVGO | Broadcom |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.